The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06393452
Recruitment Status : Recruiting
First Posted : May 1, 2024
Last Update Posted : June 14, 2024
Information provided by (Responsible Party):
Pelage Pharmaceuticals, Inc.

Brief Summary:
The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 days of administration.

Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Drug: PP405 0.05% Topical Gel Drug: PP405 Topical Vehicle Gel Phase 2

Detailed Description:
Safety, Pharmacokinetics, and Efficacy Study of PP405 in subjects with Androgenetic Alopecia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia
Actual Study Start Date : June 5, 2024
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : February 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: PP405 0.05% Topical Gel
0.05% Topical Gel applied once daily
Drug: PP405 0.05% Topical Gel
PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)

Placebo Comparator: PP405 Topical Vehicle Gel
Placebo Topical Gel applied once daily
Drug: PP405 Topical Vehicle Gel
PP405 Vehicle = placebo

Primary Outcome Measures :
  1. Percentage of subjects with treatment-related adverse events [ Time Frame: Baseline to Day 28 ]
    Collection of adverse events, treatment emergent adverse events and serious adverse events.

  2. Change in local dermal tolerability as assessed by subject and investigator [ Time Frame: Baseline to Day 28 ]
    Collection of local skin reactions using a 4 point scale (0-none, 1-mild, 2-moderate, 3-severe)

Secondary Outcome Measures :
  1. Pharmacokinetics of PP405 [ Time Frame: Baseline to Day 28 ]
    To assess the concentration of PP405 in plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male or female subjects aged 18 to 55 years.
  2. Able and willing to provide written informed consent.
  3. Males must have an AGA modified Norwood-Hamilton Classification score of Type III vertex, Type IV or Type V. Females must have a Savin classification score of I-2, I-3 or I-4.
  4. Agree to comply with protocol procedures

Exclusion Criteria:

  1. Concomitant diagnosis of non-AGA forms of alopecia.
  2. Use of other hair loss treatments within periods specified in protocol.
  3. Use of excluded medications as specified in protocol.
  4. Diagnosis of other medical conditions as specified in protocol.
  5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT06393452

Layout table for location contacts
Contact: Lisa Sherman 213-218-3830

Layout table for location information
United States, California
California Dermatology & Clinical Research Institute Not yet recruiting
Encinitas, California, United States, 92024
Clinical Trials Research Institute Not yet recruiting
Thousand Oaks, California, United States, 91320
United States, Indiana
Dawes Fretzin Clinical Research Group, LLC Recruiting
Indianapolis, Indiana, United States, 46250
Contact: Megan Kirchner    317-516-5030 ext 105   
United States, Minnesota
Minnesota Clinical Study Center Recruiting
New Brighton, Minnesota, United States, 55112
Contact: Allie Horita    763-571-4200   
United States, Texas
DermResearch Recruiting
Austin, Texas, United States, 78759
Contact: Cynthia Sanchez Bautista    512-349-0500   
Stride Clinical Research LLC Not yet recruiting
Sugar Land, Texas, United States, 77479
United States, Utah
Jordan Valley Dermatology Center Recruiting
South Jordan, Utah, United States, 84095
Contact: Kadie Van Roosendaal    801-316-0266   
United States, Virginia
Virginia Clinical Research, Inc. Not yet recruiting
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Pelage Pharmaceuticals, Inc.
Layout table for investigator information
Study Chair: Christina Weng Pelage Pharmaceuticals
Layout table for additonal information
Responsible Party: Pelage Pharmaceuticals, Inc. Identifier: NCT06393452    
Other Study ID Numbers: PP405-2001
First Posted: May 1, 2024    Key Record Dates
Last Update Posted: June 14, 2024
Last Verified: June 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical